Enozertinib

Enozertinib
Clinical data
Other names	ORIC 114; VRN 07
Identifiers
	IUPAC name N-[2-[4-(4-cyclopropylpiperazin-1-yl)piperidin-1-yl]-5-[[6-[(3R)-3-(3,5-difluorophenyl)-1,2-oxazolidin-2-yl]pyrimidin-4-yl]amino]-4-methoxyphenyl]prop-2-enamide;
CAS Number	2489185-38-6;
PubChem CID	155696192;
IUPHAR/BPS	13744;
UNII	DU24UP8R94;
Chemical and physical data
Formula	C35H42F2N8O3
Molar mass	660.771 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC1=C(C=C(C(=C1)N2CCC(CC2)N3CCN(CC3)C4CC4)NC(=O)C=C)NC5=CC(=NC=N5)N6[C@H](CCO6)C7=CC(=CC(=C7)F)F;
	InChI InChI=InChI=1S/C35H42F2N8O3/c1-3-35(46)41-28-19-29(40-33-21-34(39-22-38-33)45-30(8-15-48-45)23-16-24(36)18-25(37)17-23)32(47-2)20-31(28)44-9-6-27(7-10-44)43-13-11-42(12-14-43)26-4-5-26/h3,16-22,26-27,30H,1,4-15H2,2H3,(H,41,46)(H,38,39,40)/t30-/m1/s1; Key:NNDXFTMFJKUUQA-SSEXGKCCSA-N;

Enozertinib is an investigational new drug that is being developed by Voronoi for the treatment of solid tumors and non-small cell lung cancer. It is a EGFR receptor antagonist.^[1]^[2]

References

↑ "Enozertinib". AdisInsight. Springer Nature Switzerland AG. Retrieved 3 July 2026.
↑ Junttila MR, Repellin CE, Salaniwal S, Warne R, Lee Y, Kim H, et al. (February 2026). "Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non-Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations". Cancer Research. 86 (3): 759–772. doi:10.1158/0008-5472.CAN-25-3502. PMID 41196054.